Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series

Overview of attention for article published in Frontiers in immunology, July 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 34,012 followers.

RT @FrontImmunol: New Research: Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series https://t.co/2Y…

RT @FrontImmunol: New Research: Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series https://t.co/2Y…

RT @FrontImmunol: New Research: Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series https://t.co/2Y…

New Research: Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series https://t.co/2Yo7INy2Hw #FrontiersIn #Immunology

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.